TurboMice™ The Next-Generation Technology Expediting Mouse Model Creation
TurboMice™
Optimized Tetraploid Complementation Technology
The Next-Generation Technology Expediting
Mouse Model Creation


Utilizing TurboMice™ technology, the model preparation period can be cut to as short as 2-4 months.

Flexible Strain Selection
Maintain genetic integrity

In situ precise gene editing

Unique EnhancerPlus Analisis Platform

Multi-locus gene editing


Long fregment gene editing

In 2020, the TurboMice™ technology was leveraged to rapidly produce homozygous humanized ACE2 mice in March and then produce more than 500 homozygous humanized ACE2 mice before October for COVID-19 drug and vaccine studies.

TurboMice™ technology offers more flexibility with a variety of inbred and outbred strains to choose from (including Balb /c, 129, C57BL/6, etc.).



Top-level gene editing technology:
In situ precise gene editing with precise gene expression levels and accurate tissue specificity.


Expression Level Improved:
MingCeler's proprietar EnhancerPlus platform can help our customers improve the expression levels of humanized genes.


Fast Iteration:
MingCeler's proprietar EnhancerPlus platform can help our customers improve the expression levels of humanized genes.


Fast Iteration:
In 2020, MingCeler has upgraded the ACE2 humanized mouse model through four iterations via EnhancerPlus optimization and codon optimization, with the expression level of humanized ACE2 eventually reaching near the endogenous expression of mouse ACE2.


TurboMice™ technology gives the advantages of high accuracy in inserting location, long fragment insertion, and multiple genetically modified loci, with no allelic segregation issues.



>20kb long fragment:
TurboMice™ technology enables precise gene editing of long fragments of >20kb.

Application:
Facilitating the rapid production of complex models such as humanization, conditional knock-out (CKO), and large fragment knock-in (KI).

